I ʻApelila 2019, ua komo ʻo HopeMed i kahi ʻaelike laikini kūʻokoʻa honua me Bayer AG i ka hoʻomohala ʻana a me ka hoʻolaha ʻana o kahi antibody monoclonal kanaka e kuhikuhi ana i ka mea hoʻokipa PRL no ka mālama ʻana i ka lauoho lauoho kāne a me ka wahine, endometriosis, a me nā maʻi maʻi ʻē aʻe me ka dysregulated prolactin. (PRL) hōʻailona. Ua hōʻike kēia antibody i nā hiʻohiʻona maikaʻi loa i nā hoʻohālike holoholona me nā hiʻohiʻona NHP a me ka noiʻi palekana kanaka. ʻO kāna mau lapaʻau no ʻelua mau hōʻailona nui, endometriosis a me androgenetic alopecia, ua ʻae ʻia ʻelua e ka US FDA no nā hoʻokolohua lapaʻau Phase II. Ua hoʻomaka mua ka hoʻāʻo ʻana o ka lāʻau lapaʻau o ka HMI-115 i ka endometriosis ma ka US ma ka hopena o 2021. ʻO kāna Phase II hoʻokolohua lapaʻau no ka mālama ʻana i ka androgenetic alopecia he kikowaena honua lehulehu, randomized, double-blind, placebo- hoʻopaʻa haʻawina, i hoʻolālā ʻia e hana ʻia ma ʻAmelika Hui Pū ʻIa, Australia a me nā ʻāina ʻē aʻe.
Ua ʻōlelo ʻo Kauka Henri Doods, ka Luna Nui o HopeMed, "Haʻaheo loa wau no ka ʻae ʻana o ka FDA i kā mākou IND ʻelua he mea nui ia no kā mākou hui ʻōpio. He hana koʻikoʻi ia i kā mākou misionari e lawe mai i nā huahana First-in-Class a ʻokoʻa loa i nā maʻi. ʻO ka endometriosis a me ka alopecia nā hōʻailona kahi e kali nui ai nā maʻi i nā koho lapaʻau hou me ka maikaʻi a me ka palekana. ʻO ka holomua o ka loaʻa ʻana o ʻelua ʻae IND i loko o ia manawa pōkole he mea paipai ia no ka hui holoʻokoʻa. Manaʻo nui mākou e hoʻoikaika a hoʻonui i kā mākou mau hana R&D e lawe mai i nā koho therapeutic hou i nā poʻe maʻi ma ka honua holoʻokoʻa.
